Advertisement

Mechanical Circulatory Support: LVAD in Heart Failure

  • Aldo CannataEmail author
  • Claudio Francesco Russo
Chapter

Abstract

Advanced heart failure is a serious medical condition with a poor prognosis despite optimal medical management. Heart transplantation remains the gold standard for the treatment of advanced heart failure, but it is severely limited by chronic donor shortage. In such scenario, contemporary continuous flow LVAD is emerging as an alternative to transplant in very selected patients. A thorough evaluation of the right ventricular function is mandatory before implantation because the device will support only the left ventricle. Survival is 80 and 70% at 1 and 2 years after LVAD implantation, respectively. During support, patients experience a significant improvement in functional status and quality of life, even if it is still inferior when compared to heart transplantation. LVAD also allows the treatment of severe reversible pulmonary hypertension, decreasing the risk of the transplantation. Most frequent complications observed during support are bleeding and infection. LVAD thrombosis, albeit much less frequent, is a life-threatening event that can lead to pump stop and even death. Treatment options for thrombosis are thrombolytic therapy, LVAD replacement, and urgent transplantation.

References

  1. 1.
    Bjork JB, Alton KK, Georgiopoulou VV, Butler J, Kalogeropoulos AP. Defining advanced heart failure: a systematic review of criteria used in clinical trials. J Card Fail. 2016;22(7):569–77.CrossRefGoogle Scholar
  2. 2.
    Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al.; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: thirty-third adult heart transplantation Report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35(10):1158–69.Google Scholar
  3. 3.
    Eurotransplant International Foundation. Annual Report 2015. https://www.eurotransplant.org/cms/mediaobject.php?file=AR_ET_20153.pdf.
  4. 4.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al.; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.Google Scholar
  5. 5.
    Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015;34(12):1495–504.CrossRefGoogle Scholar
  6. 6.
    Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Third INTERMACS annual report: the evolution of destination therapy in the United States. J Heart Lung Transplant. 2011;30(2):115–23.CrossRefGoogle Scholar
  7. 7.
    Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. Eur J Heart Fail. 2017;19(5):595–602.CrossRefGoogle Scholar
  8. 8.
    Peura JL, Colvin-Adams M, Francis GS, Grady KL, Hoffman TM, Jessup M, et al.; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. Circulation. 2012;126(22):2648–67.Google Scholar
  9. 9.
    Hayek S, Sims DB, Markham DW, Butler J, Kalogeropoulos AP. Assessment of right ventricular function in left ventricular assist device candidates. Circ Cardiovasc Imaging. 2014;7(2):379–89.CrossRefGoogle Scholar
  10. 10.
    Cannata A, Petrella D, Russo CF, Bruschi G, Fratto P, Gambacorta M, et al. Postsurgical intrapericardial adhesions: mechanisms of formation and prevention. Ann Thorac Surg. 2013;95(5):1818–26.CrossRefGoogle Scholar
  11. 11.
    Cannata A, Petrella D, Gambacorta M, Russo CF, Bruschi G, Martinelli L. Histological findings following use of CoSeal in a patient with a left ventricular assist device. Surg Innov. 2013;20(6):NP35–7.CrossRefGoogle Scholar
  12. 12.
    Vitali E, Russo C, Tiziano C, Lanfranconi M, Bruschi G. Modified pericardial closure technique in patients with ventricular assist device. Ann Thorac Surg. 2000;69(4):1278–9.CrossRefGoogle Scholar
  13. 13.
    Starling RC, Estep JD, Horstmanshof DA, Milano CA, Stehlik J, Shah KB, et al.; ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP Study 2-Year Results. JACC Heart Fail. 2017. pii:S2213-1779(17)30164-6.Google Scholar
  14. 14.
    Emin A, Rogers CA, Banner NR, Steering Group, UK Cardiothoracic Transplant Audit. Quality of life of advanced chronic heart failure: medical care, mechanical circulatory support and transplantation. Eur J Cardiothorac Surg. 2016;50(2):269–73.CrossRefGoogle Scholar
  15. 15.
    Jakovljevic DG, McDiarmid A, Hallsworth K, Seferovic PM, Ninkovic VM, Parry G, et al. Effect of left ventricular assist device implantation and heart transplantation on habitual physical activity and quality of life. Am J Cardiol. 2014;114(1):88–93.CrossRefGoogle Scholar
  16. 16.
    Arnold SV, Jones PG, Allen LA, Cohen DJ, Fendler TJ, Holtz JE, et al. Frequency of poor outcome (death or poor quality of life) after left ventricular assist device for destination therapy: results from the INTERMACS Registry. Circ Heart Fail. 2016;9(8). pii: e002800.Google Scholar
  17. 17.
    Grady KL, Wissman S, Naftel DC, Myers S, Gelijins A, Moskowitz A, et al. Age and gender differences and factors related to change in health-related quality of life from before to 6 months after left ventricular assist device implantation: Findings from Interagency Registry for Mechanically Assisted Circulatory Support. J Heart Lung Transplant. 2016;35(6):777–88.CrossRefGoogle Scholar
  18. 18.
    Gupta S, Woldendorp K, Muthiah K, Robson D, Prichard R, Macdonald PS, et al. Normalisation of haemodynamics in patients with end-stage heart failure with continuous-flow left ventricular assist device therapy. Heart Lung Circ. 2014;23(10):963–9.CrossRefGoogle Scholar
  19. 19.
    Mikus E, Stepanenko A, Krabatsch T, Loforte A, Dandel M, Lehmkuhl HB, Hetzer R, Potapov EV. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg. 2011;40(4):971–7.PubMedGoogle Scholar
  20. 20.
    Healy AH, Baird BC, Drakos SG, Stehlik J, Selzman CH. Impact of ventricular assist device complications on posttransplant survival: an analysis of the United network of organ sharing database. Ann Thorac Surg. 2013;95(3):870–5.CrossRefGoogle Scholar
  21. 21.
    Pereda D, Conte JV. Left ventricular assist device driveline infections. Cardiol Clin. 2011;29:515–27.CrossRefGoogle Scholar
  22. 22.
    Goldstein DJ, Naftel D, Holman W, Bellumkonda L, Pamboukian SV, Pagani FD, et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant. 2012;31(11):1151–7.CrossRefGoogle Scholar
  23. 23.
    Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, Stevenson LW, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2014;33(1):12–22.CrossRefGoogle Scholar
  24. 24.
    Pae WE, Connell JM, Adelowo A, Boehmer JP, Korfer R, El-Banayosy A, et al.; Clinical Utility Baseline Study (CUBS) Group. Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe. J Heart Lung Transplant. 2007;26(3):219–29.CrossRefGoogle Scholar
  25. 25.
    Bocan KN, Sejdić E. Adaptive transcutaneous power transfer to implantable devices: a state of the art review. Sensors (Basel). 2016;16(3). pii:E393.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Cardiac SurgeryNiguarda HospitalMilanItaly
  2. 2.Department of Cardiac and Thoraco-Vascular SurgeryASST Grande Ospedale Metropolitano NiguardaMilanItaly

Personalised recommendations